Age: 57.0
Sex: F
Vaccine: VARZOS, VARZOS
Symptoms: Computerised tomogram head, Electroencephalogram, Encephalitis, Lumbar puncture, Nuclear magnetic resonance imaging brain
Clinical narrative: Memory loss described as memory lapses at work, difficulty recognizing known people, and stressed in making appropriate decisions; Headache; stressed in making appropriate decisions; Encephalitis; difficulty recognizing known people; Passing Out; Spells described as lightheadedness/Felt faint; This case was reported by a consumer via call center representative and described the occurrence of encephalitis in a 57-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.   The patient's past medical history included shingles (experienced 22 years before the date of reporting around waist). The patient had a Family History of diabetes (father).   On 21st January 2019, the patient received the 1st dose of Shingrix. In January 2019, 2 days after receiving Shingrix, the patient experienced encephalitis (serious criteria hospitalization and GSK medically significant) and prosopagnosia (serious criteria hospitalization). On 23rd January 2019, the patient experienced passed out (serious criteria hospitalization and GSK medically significant) and light headedness (serious criteria hospitalization). On an unknown date, the patient experienced memory loss (serious criteria hospitalization), headache (serious criteria hospitalization) and stress (serious criteria hospitalization). In January 2019, the outcome of the passed out and light headedness were recovered/resolved. On an unknown date, the outcome of the encephalitis, prosopagnosia and stress were unknown and the outcome of the memory loss and headache were not recovered/not resolved.   It was unknown if the reporter considered the encephalitis, prosopagnosia, memory loss, passed out, light headedness, headache and stress to be related to Shingrix.  Additional details were provided as follows: The case was a legally significant case. The patient received Shingrix in unknown arm and within 2 hours the patient knew something was wrong.  The patient experienced lightheadedness and felt as if about to pass out. It was reported that, it occurred 3-4 times a day and lasted for approximately 1 week and became progressively worse no matter if sitting at desk at work or standing up. The patient had an instance at bedtime seeing stars and contacting doctor the following day who advised her that she might end up passing out and visit emergency room (ER) immediately. It was reported that, the patient's physicians considered having blood washed out. The patient was being on several boards in her county and hospital and reported some people stayed away from receiving Shingrix vaccine due to her complications although she advised them not to receive Shingrix due to the debilitation of shingles. The patient was hospitalized for a few weeks, transferred to a regional hospital, due to encephalitis. It was reported that, Shingrix attacked whole body including brain resulting in memory loss described as memory lapses at work, difficulty recognizing known people, and stressed in making appropriate decisions.  The patient was treated with Keppra to help with brain, 7,000 mg of undisclosed steroids, insulin and blood pressure medicine while hospitalized. In September 2019, Keppra was discontinued and at the time of reporting, the neurologist visited for every 3 months. The Patient experienced headaches not being as severe and medication taken for relief only if headache pain is 5 or more. The reporter would follow up with her attorney that she contacted manufacturer. The reporter agreed to be in a clinical trial.The reporter consented to follow-up to her home and HCP follow up. This case has been linked with case US2019AMR201626, reported by the same reporter.